Genfit (GNFT) investor relations material

Strategic highlights and value drivers

• Ipsen's Iqirvo® in PBC achieved over $200M in first full year sales, strengthening financials.

• MASH diagnostics market is expanding, driven by $1B first-year therapeutics sales and demand for non-invasive tests.

• GNS561 in CCA shows promising safety and antitumor activity, with a novel combination approach.

• G1090N/NTZ in ACLF demonstrates a safe profile and multi-modal activity, advancing to proof-of-concept studies.

• Ipsen launched Phase 3 for Iqirvo® in PSC, targeting a market comparable to PBC 2L.

Financial and corporate highlights

• Over 25 years of experience in liver diseases, advancing assets to commercial stage.

• Received €105.5M in milestones and €24.5M in royalties from Iqirvo® sales.

• Cash position of €101.1M at 4Q25, with additional €47M expected and no debt overhang.

• Cash runway extends beyond 2028, supported by milestone and royalty revenues.

Product and pipeline updates

• Iqirvo® (elafibranor) launched in PBC, with strong global sales and withdrawal of a competitor in the US.

• MASH diagnostics technology recognized in international guidelines and supported by major consortia.

• NASHnext® test by Labcorp received US reimbursement, expanding diagnostic reach.

• GNS561 combination therapy in CCA demonstrated disease stabilization and tumor shrinkage in Phase 1b.

• G1090N/NTZ showed favorable safety and anti-inflammatory activity in Phase 1, advancing to Phase 2.